<p>Glaucoma is a group of eye conditions that damage the optic nerve, often due to high pressure within the eye. This pressure, known as intraocular pressure, can gradually lead to vision loss if left untreated. The condition typically develops slowly and painlessly, making it difficult for individuals to notice changes in their vision until significant damage has occurred.</p>
<p>&nbsp;</p>
<p>There are different types of glaucoma, with primary open-angle glaucoma being the most common. Risk factors for glaucoma include age, family history, and certain medical conditions like diabetes. Early detection through regular eye exams is crucial for managing glaucoma and preventing permanent vision loss, as treatment options such as eye drops, medication, or surgery can help control intraocular pressure.</p>
<h2><strong>Glaucoma Epidemiological Segmentation</strong></h2>
<p>The Epidemiological Segmentation of Glaucoma in 7MM from 2020 to 2034 is segmented as:-</p>
<ul>
<li>Total Prevalent Cases&nbsp;</li>
<li>Total Diagnosed Prevalent Cases&nbsp;</li>
<li>Type-specific Diagnosed Prevalent Cases</li>
<li>Type-specific Diagnosed Prevalent Cases of Open-angle Glaucoma</li>
<li>Gender-specific Diagnosed Prevalent Cases</li>
<li>Age-specific Diagnosed Prevalent Cases&nbsp;</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/glaucoma-epidemiology-forecast-insight"><span style="text-decoration: underline;"><strong>Glaucoma Epidemiology</strong></span></a></h2>
<ul>
<li>The total diagnosed cases of glaucoma in the United States were approximately 35% of the 7MM in 2023, with cases expected to rise in the forecast period.</li>
<li>In Japan, 22% of the diagnosed glaucoma cases in the 7MM were reported in 2023.</li>
<li>In EU4 and the UK, diagnosed glaucoma cases accounted for approximately 43% of the 7MM in 2023.</li>
<li>Overall, 54% of females and 46% of males in the 7MM were diagnosed with glaucoma in 2023.</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/glaucoma-market"><span style="text-decoration: underline;"><strong>Glaucoma Market</strong></span></a></h2>
<p>The Glaucoma market size in the 7MM was around USD 1.6 billion in 2023.</p>
<h2>Glaucoma Market Drivers:</h2>
<ul>
<li>Rising global prevalence of glaucoma boosting demand for innovative diagnostics and treatments.</li>
<li>Technological advancements enabling early detection and improved disease management.</li>
<li>Collaborative efforts among stakeholders fostering comprehensive care strategies.</li>
<li>Awareness campaigns enhancing treatment adherence and follow-up care.</li>
</ul>
<h2>Glaucoma Market Barriers:</h2>
<ul>
<li>Poor patient compliance with lifelong treatments and follow-ups.</li>
<li>Limited access to advanced care in low-resource settings.</li>
<li>High costs of innovative therapies and surgical options.</li>
<li>Non-adherence to prescribed treatments undermining long-term effectiveness.</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/glaucoma-pipeline-insight"><span style="text-decoration: underline;"><strong>Glaucoma Emerging Drugs</strong></span></a></h2>
<p>The emerging drugs of the Glaucoma market are</p>
<ul>
<li>NCX-470</li>
<li>PDP-716</li>
<li>Sepetaprost/ONO- 9054/DE- 126/STN-1012600</li>
<li>TRS01</li>
</ul>
<p>And others.</p>
<h2><strong>Glaucoma Key Players</strong></h2>
<p>The key players in the Glaucoma market are</p>
<ul>
<li>Nicox Ophthalmics</li>
<li>Sun Pharma Advanced Research Company Limited (SPARC)/Visiox Pharma</li>
<li>Santen Pharmaceutical</li>
<li>Tarsier Pharma</li>
</ul>
<p>And others.</p>

Glaucoma Market Size and Share Analysis Infographic

Glaucoma Market Infographic

Glaucoma Market

Glaucoma Market Infographic provides insights into the Market Size, Share, Trends, Treatment, Epidemiology, Key Companies, and Emerging Therapies